Drug intelligence / Profile preview

Flynta

Development stage: Unknown
Lead developer: Apeks Pharma
Modality: Small Molecules
Administration: Oral

Overview

Flynta is a film-coated tablet formulation of tadalafil, a small molecule phosphodiesterase 5 (PDE5) inhibitor. It is marketed by Apeks Pharma and manufactured by İlko İlaç. Tadalafil works by inhibiting the PDE5 enzyme, which leads to increased levels of cyclic guanosine monophosphate (cGMP) in the smooth muscle of the corpus cavernosum and the prostate, resulting in smooth muscle relaxation and increased blood flow. Flynta is indicated for the treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (BPH). It is available in 5 mg and 20 mg strengths and requires sexual stimulation to be effective for erectile dysfunction.

Brand names: Flynta
Other names: tadalafil

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on Flynta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flynta.

Explore the full profile